NMS · Biotechnology

AVXL (AVXL) Stock

$2.49 -3.11% NMS: AVXL Healthcare

Valuation

MetricValue
Price$2.49
Market Cap$230.75M
P/E Ratio-5.02
P/B Ratio2.64
P/S Ratio0.00
EPS (TTM)$-0.54
52-Week High$13.99
52-Week Low$2.32
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-48.42%
ROA-44.23%
ROCE-53.68%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio11.56

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-42.0M$-51.0M$-56.0M$-53.0M$-51.0M
Net Profit$-38.0M$-48.0M$-48.0M$-43.0M$-46.0M
EPS$-0.54$-0.62$-0.60$-0.52$-0.54
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$162.0M$153.0M$154.0M$136.0M$104.0M
Total Liabilities$11.0M$10.0M$13.0M$15.0M$9.0M
Cash$152.0M$149.0M$151.0M$132.0M$103.0M
Borrowings$0$0$0$0$0

Latest News

Penny Stocks To Watch In May 2026 Simply Wall St. · May 29, 2026 Exploring High Growth Tech Stocks In The US Market May 2026 Simply Wall St. · May 28, 2026 Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification GlobeNewswire · May 22, 2026 CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus InvestorsHub · May 6, 2026 Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer GlobeNewswire · May 6, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-30.0M$-24.0M$-28.0M$-31.0M$-39.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$-1.0M$0$0$-3.0M
Net Cash Flow$123.0M$-3.0M$2.0M$-19.0M$-30.0M
Free Cash Flow$-30.0M$-24.0M$-28.0M$-31.0M$-39.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-13.37%
Quick Ratio20.87
Interest Coverage—
Return 1Y-79.39%
Return 3Y-68.47%
Return 5Y-88.30%

Ownership

Insiders Held3.12%
Institutions Held43.85%
Institutions Float Held45.26%
Institutional HolderSharesReport Date
Blackrock Inc.7,609,6182026-03-31
State Street Corporation4,512,0282026-03-31
Vanguard Capital Management LLC3,863,9502026-03-31
Two Sigma Investments, LP3,247,8882026-03-31
Geode Capital Management, LLC2,188,2752026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About AVXL

AVXL is led by CEO Christopher U. Missling, employs 42 people, headquartered in US, publicly traded since 2006.

AVXL stock trades at $2.49 with a market capitalization of $230.75M. The stock is valued at a price-to-earnings (P/E) ratio of -5.02, price-to-book of 2.64, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.32 and $13.99, and currently trades 82.2% below its 52-week high.

On profitability, AVXL generates a return on equity (ROE) of -48.42%, return on capital employed of -53.68%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides